Melitrix builds its own portfolio of specialty pharmaceuticals, generics, and consumer health products, and partners with other companies to develop, manufacture, and launch across new markets, backed by an established European and Indian manufacturing and regulatory network.
Our own products fund and inform our development work. Our development work strengthens our manufacturing and regulatory network. Each part makes the others sharper.
Specialty pharmaceutical programs on the 505(b)(2) pathway, a generic pipeline of sterile injectables, liquids, and oral solids, and a consumer health range of color cosmetics and nutraceuticals.
See the platformRegulatory strategy, formulation development, and market-access support for companies moving a product toward approval, or into a new territory, without building the function in-house.
Development servicesAccess to dedicated European capacity for sterile injectables and liquids, plus a vetted network of manufacturing and distribution partners across Europe, India, and emerging markets.
Manufacturing accessProgram and pipeline details are shared with qualified partners under confidentiality.
Melitrix is privately held and not raising capital. That lets us choose programs and partners on merit, and stay with them.
Development, regulatory, manufacturing, and commercial capability sit under one roof, so a program does not lose momentum handing off between vendors.
Our manufacturing and R&D partners are established operators in Europe and India, with distribution reach into EMEA and emerging markets.
We work fluently across ANDA, 505(b)(2), EU-GMP, and consumer health frameworks, and we plan submissions before we start formulation.
Every program has to show a credible path to a better outcome or better access. Commercial opportunity alone is not a reason to advance one.
Whether you need development support, manufacturing capacity, a licensing conversation, or a distribution partner, we would like to hear about it.